



PRESS RELEASE

22 April 2025 08:30:00 CEST

Invitation to a digital company presentation about AcouSort

AcouSort AB (publ) (the “Company”) invites to a digital company presentation on **Thursday, April 24, 2025, at 16:00 CEST.**

During the company presentation, Commercial Director, Agnes Michanek, will introduce the Company and review its latest developments. There will be an opportunity to submit written questions during the broadcast, which will be answered during the subsequent Q&A session along with potential additional questions. The presentation will be held in English.

Time: Thursday, April 24, 2025, at 16:00 CEST.

Location: The webcast and presentation material will be available on the following link, where you will have the opportunity to ask questions: <https://tinyurl.com/2s395vph>

For those unable to attend the company presentation on April 24, AcouSort, through BioStock, has pre-recorded and published a presentation. The pre-recorded presentation via BioStock can be found here:

[BioStock Investor Pitch: AcouSort - BioStock](#)

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).